A Phase 1/2 interventional study of Bcl-2 Inhibitor GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia and Refractory Chronic Lymphocytic Leukemia, sponsored by Kerry Rogers. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Kerry Rogers · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 28th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1/2, reaches primary completion later than 2 of the 41 other live ones, and was the 11th registered.
2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Kerry Rogers · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
City of Hope Medical Center · Sites in United States
Ages 18+
Zulfa Omer · Sites in United States
Ages 18+
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 44 · Phase 3 15 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 39 across 1,605 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 69 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 69 have an industry lead sponsor. The 10 most frequent:
Kerry Rogers is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Kerry Rogers has 4 studies filed under Leukemia, Lymphocytic, Chronic, B-Cell — fewer than ten, so there is no comparison to draw.
13 of the studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has returned (relapsed), does not respond to treatment (refractory), or is previously untreated. Bcl-2 inhibitor GDC-0199 and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may block cancer growth in different ways by targeting certain cells. Giving Bcl-2 inhibitor GDC-0199 together with obinutuzumab and ibrutinib may be a better treatment for chronic lymphocytic leukemia.
PRIMARY OBJECTIVES:
I. To identify the dose of venetoclax (Bcl-2 inhibitor GDC-0199) that can be safely administered in combination with obinutuzumab and ibrutinib for the treatment of relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL).
II. To evaluate the feasibility, safety, and tolerability of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated CLL.
III. To determine the minimal residual disease (MRD)-negative complete response (CR) rate after 12 cycles of treatment with venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated CLL.
SECONDARY OBJECTIVES:
I. To determine the overall response rate (ORR) and complete response rate (CR) of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated patients with CLL.
II. To estimate progression free survival (PFS) after treatment with venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated patients with CLL.
III. To conduct pharmacokinetic and pharmacodynamic studies of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated patients with CLL.
IV. To examine pre-treatment and serial biomarkers associated with response and mechanisms of resistance to venetoclax, obinutuzumab and ibrutinib when given in combination for relapsed/refractory or previously untreated patients with CLL.
OUTLINE: This is a phase Ib, dose-escalation study of Bcl-2 inhibitor GDC-0199 followed by a phase II study.
Patients receive obinutuzumab intravenously (IV) on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 4 and 8 weeks, every 3 months for 2 years, and then every 6 months thereafter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CLL patients must meet the following requirements:
Treatment-naïve CLL patients must meet the following requirements (Phase II only):
Female patients must be surgically sterile, (for at least 1 year), or have negative results from a pregnancy test performed as follows:
All female patients not surgically sterile or post-menopausal (for at least 1 year) and non-vasectomized male patients must practice at least one of the following methods of :
Non-vasectomized male patients must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 3 months after study treatment:
Exclusion Criteria:
Positive hepatitis serology:
virus (HBV): patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); patients who are positive for anti-HBc may be considered for inclusion in the study on a case-by-case basis if they are hepatitis B viral deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA testing by real-time polymerase chain reaction (PCR); patients with positive serology may be referred to a hepatologist or gastroenterologist for appropriate monitoring and management
History of other active other than CLL within the past 3 years prior to study entry, with the exception of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
Drug: Bcl-2 Inhibitor GDC-0199 · Biological: Obinutuzumab · Drug: Ibrutinib · Other: Pharmacological Study · Other: Laboratory Biomarker Analysis · Other: Quality-of-Life Assessment
Given PO
Also known as: ABT-0199, ABT-199, GDC-0199, RG7601
Given IV
Also known as: Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759
Given PO
Also known as: BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
Correlative studies
Also known as: pharmacological studies
Correlative studies
Ancillary studies
Also known as: Quality of Life Assessment
Maximum Tolerated Dose of Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib (Phase Ib)
Time frame: 28 days (course 3)
Minimal Residual Disease (MRD)-Complete Response (CR) Defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria (Phase II)
Assessments of MRD will be used in patients classified as CR to further evaluate their status as disease-free and if this further impacts their ability to remain progression-free and alive. MRD will be determined by high sensitivity 4 color flow cytometric analysis of the bone marrow using validated panels.
Time frame: Up to 8 weeks post-treatment
Number of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
For all patients who receive at least one day of treatment, toxicities will be tabulated by type and grade and displayed in summary form. Serious adverse events are listed with "(SAE)" after the event name.
Time frame: Up to 4 years
Number of Courses Started/Completed
May be summarized.
Time frame: Up to 14 months
Number of Patients Who Reach the Target Dose of Bcl-2 Inhibitor GDC-0199
May be summarized.
Time frame: Up to 14 months
Number of Patients Requiring Dose Reductions
May be summarized.
Time frame: Up to 14 months
Reason for Going Off Treatment
May be summarized.
Time frame: Up to 14 months
Overall Response Rate
Overall response rate will be reported for all evaluable patients in the phase II setting, within and potentially across cohorts, assuming a binomial distribution.
Time frame: Up to 4 years
Progression-free Survival (PFS)
Will be summarized by the Kaplan-Meier method for each of the phase II cohorts.
Time frame: Time from first treatment date until the date of progression or death, whichever occurs first, assessed up to 8 years
Emotional Distress Assessment
Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Mental Component Scale (MCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better mental health. Scores for the MCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.
Time frame: Cycle 1 day 1, cycle 2 day 1, cycle 3 day 1, cycle 6 day 1 and cycle 12 day 1
Health Related Quality of Life
Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Physical Component Scale (PCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better physical health. Scores for the PCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.
Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 6 Day 1, and Cycle 12 Day 1 (each cycle is 28 days)
Serial Assessment of Immune Effector Cell Number and Function.
Peripheral blood immunophenotyping will be used to enumerate immune effector cells (counts and percentages of T-, and Natural Killer (NK)-cell subsets).
Time frame: 4 weeks post-treatment
Baseline Prognostic Factors: Number of Prior Therapies
Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.
Time frame: Baseline
Baseline Prognostic Factors: Tumor Lysis Syndrome (TLS) Risk
Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.
Time frame: Baseline
Baseline Prognostic Factors: Hemoglobin
Time frame: Baseline
Baseline Prognostic Factors: Investigations
Absolute neutrophil count (ANC), Absolute lymphocyte count (ALC) and Platelets.
Time frame: Baseline
Baseline Prognostic Factor: Beta-2-microglobulin (B2M)
Beta-2-microglobulin (B2M)
Time frame: At baseline
Baseline Prognostic Factors: Lactate Dehydrogenase (LDH)
lactate dehydrogenase (LDH)
Time frame: At baseline
Baseline Prognostic Factors: Genetic Factors
Time frame: At baseline
| Milestone | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 6 | 25 | 25 | 25 |
| Completed | 3 | 3 | 6 | 22 | 21 | 24 |
| Not completed | 0 | 0 | 0 | 3 | 4 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 | 2 | 0 |
| milligrams | Phase 1b Cohort | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|
| Maximum Tolerated Dose of Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib (Phase Ib) | 400 | — | — | — |
Assessments of MRD will be used in patients classified as CR to further evaluate their status as disease-free and if this further impacts their ability to remain progression-free and alive. MRD will be determined by high sensitivity 4 color flow cytometric analysis of the bone marrow using validated panels.
| percentage of participants | Phase 1b Cohort | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|
| Minimal Residual Disease (MRD)-Complete Response (CR) Defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria (Phase II) | — | 44 | 56 | 60 |
For all patients who receive at least one day of treatment, toxicities will be tabulated by type and grade and displayed in summary form. Serious adverse events are listed with "(SAE)" after the event name.
| Number of Events | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Abdominal pain | 5 | 1 | 1 | 11 | 7 | 6 |
| Alanine Aminotransferase Increased | 2 | 4 | 8 | 23 | 12 | 23 |
| Alkaline Phosphatase Increased | 2 | 0 | 0 | 6 | 10 | 15 |
| Allergic Reaction | 1 | 0 | 0 | 0 | 5 | 2 |
| Allergic Rhinitis | 2 | 3 | 3 | 17 | 24 | 3 |
| Alopecia | 0 | 0 | 0 | 1 | 1 | 3 |
| Anemia | 4 | 0 | 0 | 20 | 28 | 16 |
| Anorexia | 0 | 2 | 2 | 10 | 21 | 14 |
| Anxiety | 0 | 1 | 3 | 14 | 9 | 2 |
| Arthralgia | 4 | 5 | 10 | 33 | 37 | 19 |
| Arthritis | 2 | 1 | 5 | 6 | 12 | 1 |
| Aspartate Aminotransferase Increased | 2 | 3 | 11 | 35 | 22 | 40 |
| Atrial Fibrillation | 0 | 0 | 0 | 2 | 4 | 5 |
| Back Pain | 3 | 3 | 1 | 16 | 22 | 13 |
| Blood Bilirubin Increased | 6 | 0 | 1 | 24 | 43 | 54 |
| Bloating | 1 | 0 | 0 | 1 | 1 | 8 |
| Blurred Vision | 0 | 0 | 4 | 8 | 11 | 3 |
| Bone Pain | 0 | 0 | 2 | 4 | 5 | 3 |
| Bronchial Infection | 1 | 4 | 0 | 7 | 3 | 2 |
| Bruising | 3 | 6 | 12 | 34 | 33 | 30 |
| Bullous Dermatitis | 2 | 1 | 0 | 1 | 3 | 1 |
| Cataract | 0 | 0 | 0 | 3 | 1 | 5 |
| Non-cardiac Chest Pain | 0 | 0 | 1 | 11 | 5 | 9 |
| Chest Pain - Cardiac | 0 | 0 | 1 | 4 | 2 | 1 |
| Chills | 1 | 1 | 0 | 14 | 20 | 10 |
| High Cholesterol | 1 | 0 | 1 | 7 | 4 | 1 |
| Chronic Kidney Disease | 2 | 0 | 1 | 4 | 0 | 1 |
| Confusion | 0 | 0 | 1 | 0 | 3 | 2 |
| Conjunctivitis | 1 | 0 | 0 | 2 | 2 | 2 |
| Constipation | 2 | 2 | 4 | 24 | 32 | 18 |
| Cough | 2 | 2 | 4 | 32 | 26 | 21 |
| Creatinine Increased | 7 | 7 | 8 | 32 | 27 | 25 |
| Dental Caries | 1 | 0 | 2 | 9 | 1 | 1 |
| Depression | 0 | 0 | 1 | 9 | 6 | 1 |
| Diarrhea | 4 | 5 | 16 | 46 | 44 | 63 |
| Dizziness | 2 | 1 | 6 | 11 | 19 | 16 |
| Dry Eyes | 1 | 0 | 1 | 5 | 4 | 6 |
| Dry Mouth | 1 | 0 | 2 | 1 | 3 | 1 |
| Dry Skin | 1 | 0 | 3 | 10 | 9 | 7 |
| Dysgeusia | 0 | 1 | 1 | 5 | 6 | 7 |
| Dyspepsia | 2 | 4 | 5 | 29 | 44 | 14 |
| Dysphagia | 0 | 0 | 0 | 3 | 3 | 1 |
| Dyspnea | 1 | 5 | 11 | 23 | 25 | 14 |
| Ear Pain | 0 | 0 | 0 | 2 | 5 | 4 |
| Epistaxis | 0 | 0 | 11 | 17 | 21 | 2 |
| Fall | 0 | 0 | 2 | 10 | 10 | 5 |
| Fatigue | 4 | 19 | 24 | 66 | 76 | 39 |
| Fever | 3 | 0 | 3 | 15 | 17 | 10 |
| Flatulence | 0 | 2 | 1 | 1 | 0 | 2 |
| Floaters | 0 | 0 | 1 | 2 | 0 | 2 |
| Flu Like Symptoms | 0 | 5 | 5 | 6 | 6 | 21 |
| Flushing | 0 | 0 | 1 | 1 | 2 | 2 |
| Gastroesophageal Reflux Disease | 0 | 1 | 4 | 2 | 1 | 3 |
| Headache | 5 | 6 | 6 | 35 | 27 | 23 |
| Hearing Impaired | 0 | 0 | 0 | 2 | 1 | 0 |
| Heamaturia | 1 | 0 | 0 | 5 | 8 | 3 |
| Hemorrhoids | 0 | 1 | 2 | 1 | 2 | 1 |
| Hot Flashes | 0 | 0 | 0 | 2 | 6 | 3 |
| Hyperglycemia | 5 | 0 | 7 | 53 | 40 | 31 |
| Hyperhidrosis | 4 | 7 | 4 | 17 | 24 | 12 |
| Hyperkalemia | 2 | 1 | 0 | 6 | 0 | 7 |
| Hypernatremia | 4 | 2 | 1 | 13 | 13 | 3 |
| Hypertension | 17 | 26 | 52 | 225 | 207 | 125 |
| Hyperuricemia | 6 | 5 | 20 | 55 | 37 | 28 |
| Hypoalbuminemia | 0 | 1 | 2 | 15 | 53 | 9 |
| Hypocalcemia | 3 | 17 | 11 | 74 | 98 | 56 |
| Hypoglycemia | 0 | 0 | 0 | 22 | 21 | 8 |
| Hypokalemia | 3 | 1 | 0 | 28 | 40 | 24 |
| Hypomagnesemia | 0 | 1 | 0 | 11 | 14 | 12 |
| Hyponatremia | 1 | 0 | 0 | 19 | 16 | 18 |
| Hypophosphatemia | 5 | 5 | 13 | 19 | 11 | 14 |
| Hypothyroidism | 0 | 0 | 1 | 1 | 3 | 1 |
| Infusion Related Reaction | 3 | 6 | 4 | 21 | 25 | 25 |
| Insomnia | 1 | 5 | 6 | 11 | 23 | 13 |
| Joint Range of Motion Decreased | 0 | 0 | 0 | 1 | 1 | 2 |
| Leukocytosis | 2 | 0 | 0 | 2 | 3 | 2 |
| Lung Infection | 0 | 2 | 2 | 4 | 5 | 8 |
| Lymph Node Pain | 1 | 1 | 0 | 3 | 5 | 1 |
| Lymphocyte Count Decreased | 24 | 29 | 30 | 170 | 162 | 172 |
| Lymphocyte Count Increased | 5 | 3 | 1 | 34 | 22 | 31 |
| Malaise | 0 | 0 | 0 | 1 | 5 | 4 |
| Mucositis Oral | 0 | 5 | 4 | 25 | 42 | 33 |
| Myalgia | 3 | 1 | 13 | 41 | 40 | 29 |
| Nail Loss | 0 | 2 | 1 | 8 | 6 | 0 |
| Nasal Congestion | 2 | 2 | 3 | 12 | 10 | 10 |
| Nausea | 1 | 2 | 8 | 32 | 41 | 34 |
| Neck Pain | 1 | 2 | 0 | 1 | 5 | 2 |
| Neutrophil Count Decreased | 18 | 34 | 24 | 229 | 169 | 169 |
| Oral Pain | 0 | 0 | 1 | 1 | 7 | 0 |
| Otitis Media | 0 | 0 | 0 | 3 | 3 | 5 |
| Pain | 4 | 0 | 6 | 9 | 8 | 6 |
| Palpitations | 0 | 0 | 0 | 7 | 4 | 7 |
| Paresthesia | 1 | 3 | 2 | 15 | 21 | 19 |
| Peripheral Sensory Neuropathy | 0 | 1 | 3 | 4 | 2 | 1 |
| Platelet Count Decreased | 21 | 12 | 58 | 177 | 175 | 103 |
| Postnasal Drip | 1 | 0 | 1 | 12 | 7 | 7 |
| Productive Cough | 0 | 0 | 0 | 6 | 1 | 6 |
| Proteinuria | 0 | 0 | 0 | 4 | 1 | 1 |
| Pruritus | 1 | 1 | 0 | 2 | 3 | 7 |
| Rash Acneiform | 0 | 0 | 0 | 3 | 5 | 3 |
| Rash Maculo-papular | 2 | 1 | 4 | 23 | 33 | 12 |
| Sinus Bradycardia | 1 | 0 | 2 | 36 | 20 | 29 |
| Sinus Disorder | 0 | 0 | 0 | 6 | 1 | 1 |
| Sinus Pain | 0 | 0 | 0 | 4 | 2 | 0 |
| Sinus Tachycardia | 1 | 0 | 0 | 9 | 5 | 10 |
| Sinusitis | 2 | 4 | 2 | 35 | 25 | 15 |
| Skin Infection | 1 | 0 | 8 | 13 | 11 | 6 |
| Sleep Apnea | 0 | 1 | 2 | 2 | 2 | 1 |
| Sore Throat | 0 | 1 | 3 | 12 | 17 | 11 |
| Syncope | 0 | 0 | 0 | 2 | 2 | 1 |
| Testicular Pain | 2 | 0 | 1 | 0 | 1 | 2 |
| Tinnitus | 0 | 0 | 0 | 7 | 4 | 2 |
| Toothache | 2 | 0 | 1 | 5 | 3 | 4 |
| Tremor | 0 | 0 | 1 | 0 | 1 | 4 |
| Upper Respiratory Infection | 5 | 5 | 8 | 30 | 28 | 11 |
| Urinary Frequency | 2 | 1 | 0 | 5 | 8 | 5 |
| Urinary Tract Infection | 0 | 0 | 2 | 6 | 20 | 3 |
| Vomiting | 0 | 2 | 3 | 19 | 10 | 12 |
| White Blood Cell Decreased | 19 | 34 | 24 | 231 | 184 | 186 |
| Weight Gain | 7 | 13 | 6 | 42 | 57 | 51 |
| Weight Loss | 1 | 2 | 10 | 11 | 10 | 8 |
| Activated partial thromboplastin time prolonged | 2 | 0 | 1 | 1 | 0 | 0 |
| Blood and lymphatic system disorders - Other | 1 | 1 | 0 | 2 | 0 | 3 |
| Ear and labyrinth disorders - Other | 1 | 0 | 0 | 6 | 2 | 5 |
| Eye Disorders - Other | 1 | 1 | 0 | 6 | 3 | 12 |
| Flank Pain | 1 | 0 | 0 | 0 | 1 | 2 |
| Gastrointestinal disorders - Other | 2 | 0 | 2 | 14 | 18 | 8 |
| Gum Infection | 2 | 0 | 0 | 0 | 0 | 2 |
| Injury, poisoning and procedural complications - Other | 1 | 1 | 11 | 9 | 17 | 10 |
| Musculoskeletal and connective tissue disorder - Other | 5 | 4 | 6 | 17 | 8 | 7 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other | 2 | 3 | 3 | 29 | 28 | 37 |
| Pain in Extremity | 1 | 1 | 2 | 22 | 13 | 9 |
| Pneumonitis | 2 | 0 | 0 | 0 | 3 | 0 |
| Renal and urinary disorders - Other | 2 | 0 | 0 | 1 | 1 | 0 |
| Skin and subcutaneous tissue disorders - Other | 4 | 2 | 12 | 24 | 23 | 29 |
| Surgical and medical procedures - Other | 1 | 0 | 0 | 0 | 1 | 0 |
| Urinary Retention | 1 | 0 | 0 | 3 | 0 | 2 |
| Vascular disorders - Other | 2 | 0 | 0 | 1 | 1 | 1 |
| Atrioventricular block complete | 0 | 1 | 0 | 0 | 0 | 0 |
| Cognitive Disturbance | 0 | 1 | 0 | 0 | 1 | 0 |
| Eye Infection | 0 | 1 | 0 | 0 | 1 | 0 |
| General disorders and administration site conditions - Other | 0 | 1 | 0 | 1 | 0 | 1 |
| Hypertriglyceridemia | 0 | 1 | 0 | 0 | 0 | 1 |
| Infections and infestations - Other | 0 | 1 | 3 | 17 | 28 | 35 |
| Memory Impairment | 0 | 1 | 0 | 0 | 1 | 0 |
| Metabolism and nutrition disorders - Other | 0 | 1 | 2 | 0 | 0 | 1 |
| Nail Ridging | 0 | 1 | 0 | 0 | 0 | 1 |
| Reproductive system and breast disorders - Other | 0 | 1 | 0 | 1 | 2 | 5 |
| Respiratory, thoracic and mediastinal disorders - Other | 0 | 2 | 0 | 1 | 2 | 0 |
| Rhinitis infective | 0 | 1 | 0 | 0 | 0 | 0 |
| Urinary Urgency | 0 | 1 | 0 | 0 | 0 | 1 |
| Anal Hemorrhage | 0 | 0 | 1 | 1 | 0 | 1 |
| Bladder Spasm | 0 | 0 | 1 | 0 | 1 | 0 |
| Cardiac Disorders - Other | 0 | 0 | 1 | 3 | 4 | 1 |
| Dysarthria | 0 | 0 | 3 | 0 | 1 | 0 |
| Edema Cerebral | 0 | 0 | 1 | 0 | 0 | 0 |
| Edema Face | 0 | 0 | 2 | 1 | 0 | 1 |
| Edema Limbs | 0 | 0 | 2 | 9 | 8 | 10 |
| Flashing Lights | 0 | 0 | 1 | 1 | 0 | 0 |
| Gastrointestinal Pain | 0 | 0 | 1 | 2 | 0 | 1 |
| Hematoma | 0 | 0 | 1 | 0 | 0 | 4 |
| Hypersomnia | 0 | 0 | 2 | 0 | 0 | 1 |
| Investigations - Other | 0 | 0 | 1 | 0 | 0 | 1 |
| Localized Edema | 0 | 0 | 1 | 18 | 15 | 8 |
| Osteoporosis | 0 | 0 | 1 | 0 | 1 | 2 |
| Periorbital Edema | 0 | 0 | 1 | 0 | 0 | 0 |
| Rectal Hemorrhage | 0 | 0 | 1 | 1 | 0 | 0 |
| Stomach Pain | 0 | 0 | 1 | 1 | 1 | 0 |
| Tooth Infection | 0 | 0 | 1 | 0 | 1 | 1 |
| Urinary Tract Pain | 0 | 0 | 2 | 0 | 0 | 0 |
| Vaginal Infection | 0 | 0 | 1 | 0 | 2 | 0 |
| Vertigo | 0 | 0 | 1 | 0 | 0 | 2 |
| Cholecystitis | 0 | 0 | 0 | 3 | 0 | 0 |
| Laryngeal inflammation | 0 | 0 | 0 | 4 | 0 | 1 |
| Nail Infection | 0 | 0 | 0 | 3 | 3 | 0 |
| Oral Hemorrhage | 0 | 0 | 0 | 2 | 2 | 0 |
| Otitis Externa | 0 | 0 | 0 | 2 | 1 | 1 |
| Purpura | 0 | 0 | 0 | 3 | 3 | 1 |
| Watering Eyes | 0 | 0 | 0 | 2 | 0 | 0 |
| Fracture | 0 | 0 | 0 | 1 | 3 | 0 |
| Generalized Muscle Weakness | 0 | 0 | 0 | 0 | 4 | 0 |
| Hoarseness | 0 | 0 | 0 | 0 | 3 | 2 |
| Muscle Weakness Lower Limb | 0 | 0 | 0 | 1 | 3 | 0 |
| Agitation | 0 | 0 | 0 | 0 | 1 | 2 |
| Chest Wall Pain | 0 | 0 | 0 | 1 | 0 | 2 |
| Erectile Dysfunction | 0 | 0 | 0 | 1 | 0 | 2 |
| Hiccups | 0 | 0 | 0 | 1 | 0 | 2 |
| INR increased | 0 | 0 | 0 | 0 | 0 | 2 |
| Nervous system disorders - Other | 0 | 0 | 0 | 2 | 1 | 2 |
| Neuralgia | 0 | 0 | 0 | 0 | 1 | 2 |
| Paronychia | 0 | 0 | 0 | 5 | 2 | 2 |
| Blood and lymphatic system disorders - other (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
| Febrile neutropenia | 0 | 0 | 0 | 1 | 0 | 1 |
| Atrial fibrillation (SAE) | 0 | 0 | 0 | 0 | 2 | 1 |
| Atrioventricular block complete (SAE) | 0 | 1 | 0 | 0 | 0 | 0 |
| Cardiac disorders - Other (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Chest pain - cardiac (SAE) | 0 | 0 | 0 | 2 | 0 | 0 |
| Abdominal pain (SAE) | 1 | 0 | 0 | 0 | 0 | 0 |
| Colitis (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Fatigue (SAE) | 0 | 0 | 0 | 1 | 1 | 0 |
| Fever (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Flu like symptoms (SAE) | 0 | 1 | 0 | 0 | 0 | 0 |
| Cholecystitis (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Bronchial infection (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Infections and infestations - other (SAE) | 0 | 1 | 1 | 0 | 0 | 3 |
| Lung Infection (SAE) | 0 | 1 | 1 | 1 | 1 | 2 |
| Sepsis (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Sinusitis (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Skin infection (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Upper Respiratory Infection (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Infusion related reaction (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
| Stroke (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
| Alanine Aminotransferase increased (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Aspartate aminotransferase increased (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Neutrophil count decreased (SAE) | 0 | 0 | 0 | 0 | 0 | 4 |
| Dehydration (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperkalemia (SAE) | 0 | 0 | 0 | 0 | 0 | 2 |
| Hypoglycemia (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Metabolism and nutrition disorders - other (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
| Tumor lysis syndrome (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
| Pain in extremity (SAE) | 0 | 0 | 0 | 1 | 1 | 0 |
| Headache (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Nervous system disorders - other (SAE) | 0 | 0 | 0 | 1 | 1 | 0 |
| Syncope (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Pneumonitis (SAE) | 0 | 0 | 0 | 0 | 1 | 0 |
| Wheezing (SAE) | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperhidrosis (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypertension (SAE) | 0 | 1 | 0 | 1 | 0 | 0 |
May be summarized.
| number of subjects | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Completed 14 cycles | 3 | 3 | 6 | 22 | 21 | 24 |
| Completed 13 or less cycles | 0 | 0 | 0 | 3 | 4 | 1 |
May be summarized.
| Participants | Phase 1b Cohort | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|
| Number of Patients Who Reach the Target Dose of Bcl-2 Inhibitor GDC-0199 | — | 24 | 25 | 25 |
May be summarized.
| Participants | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Number of Patients Requiring Dose Reductions | 0 | 0 | 0 | 2 | 0 | 5 |
May be summarized.
| participants | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Adverse Event | 0 | 0 | 0 | 1 | 2 | 1 |
| Physician Decision | 0 | 0 | 0 | 2 | 2 | 0 |
| Treatment completed per protocol | 3 | 3 | 6 | 22 | 21 | 24 |
Overall response rate will be reported for all evaluable patients in the phase II setting, within and potentially across cohorts, assuming a binomial distribution.
| percentage of participants | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Overall Response Rate | 66.7 | 100 | 100 | 88 | 84 | 96 |
Will be summarized by the Kaplan-Meier method for each of the phase II cohorts.
| months | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 81.8 (57.3 to NA) | 88.5 (80.6 to NA) | NA (NA to NA) |
Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Mental Component Scale (MCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better mental health. Scores for the MCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.
| T-score | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | — | 54.03 ± 9.25 | 52.32 ± 6.87 | — |
| Cycle 2 Day 1 | — | — | — | 54.42 ± 7.75 | 54.88 ± 6.10 | — |
| Cycle 3 Day 1 | — | — | — | 55.90 ± 7.05 | 54.33 ± 6.54 | — |
| Cycle 6 Day 1 | — | — | — | 56.31 ± 7.64 | 53.50 ± 8.96 | — |
| Cycle 12 Day 1 | — | — | — | 55.53 ± 5.34 | 54.35 ± 6.30 | — |
Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Physical Component Scale (PCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better physical health. Scores for the PCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.
| T-score | Phase 1b Cohort | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|
| Cycle 1 Day 1 | — | 42.88 ± 12.52 | 44.25 ± 10.97 | — |
| Cycle 2 Day 1 | — | 45.53 ± 12.12 | 42.01 ± 10.57 | — |
| Cycle 3 Day 1 | — | 45.17 ± 13.56 | 44.92 ± 11.86 | — |
| Cycle 6 Day 1 | — | 45.94 ± 12.95 | 46.75 ± 11.37 | — |
| Cycle 12 Day 1 | — | 45.97 ± 14.05 | 46.40 ± 11.45 | — |
Peripheral blood immunophenotyping will be used to enumerate immune effector cells (counts and percentages of T-, and Natural Killer (NK)-cell subsets).
| 10^3 cells/uL | Phase 1b Cohort | Phase 2 Relapsed/Refractory (RR) | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|
| NK | — | 95 ± 64 | 89 ± 49 | — |
| CD3+CD4+ | — | 499 ± 217 | 738 ± 298 | — |
| CD3+CD8+ | — | 479 ± 296 | 312 ± 213 | — |
Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.
| Number of Prior Therapies | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Baseline Prognostic Factors: Number of Prior Therapies | 1 (1 to 7) | 1 (1 to 2) | 1 (1 to 2) | 1 (1 to 3) | 0 (0 to 0) | 0 (0 to 0) |
Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.
| participants | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| TLS Risk Low | 0 | 0 | 1 | 7 | 1 | 1 |
| TLS Risk Medium | 2 | 3 | 2 | 8 | 18 | 17 |
| TLS Risk High | 1 | 0 | 3 | 10 | 6 | 7 |
| grams per deciliter | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Baseline Prognostic Factors: Hemoglobin | 12.3 (12.3 to 13.3) | 11.4 (11.2 to 12.7) | 12.7 (11.6 to 15.8) | 12 (9 to 16) | 10 (8 to 13) | 10 (7 to 15) |
Absolute neutrophil count (ANC), Absolute lymphocyte count (ALC) and Platelets.
| 10^3 cells/uL | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Platelets | 117 (103 to 227) | 158 (102 to 208) | 171.5 (139 to 222) | 132 (52 to 255) | 166 (68 to 231) | 132 (23 to 488) |
| ANC | 8.9 (0.2 to 23.5) | 2.6 (0 to 5.1) | 5.5 (3.2 to 9.9) | 3 (1 to 28) | 5 (1 to 26) | 4 (1 to 16) |
| ALC | 135.3 (19.6 to 445.6) | 144.9 (79.2 to 230.6) | 30.0 (2.8 to 287.2) | 29 (0 to 348) | 109 (3 to 413) | 191 (3 to 488) |
Beta-2-microglobulin (B2M)
| milligrams per liter | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Baseline Prognostic Factor: Beta-2-microglobulin (B2M) | 5.2 (3.9 to 6.8) | 4.2 (2.7 to 5.0) | 2.6 (2.2 to 3.4) | 4 (2 to 7) | 3 (2 to 7) | 3 (2 to 6) |
lactate dehydrogenase (LDH)
| units per liter | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Baseline Prognostic Factors: Lactate Dehydrogenase (LDH) | 293 (219 to 371) | 301 (237 to 410) | 202 (155 to 899) | 223 (131 to 725) | 230 (98 to 710) | 280 (147 to 921) |
| participants | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| High Hyperdiploid (HeH) | — | — | — | 19 | 17 | 19 |
| Zap-70 methylated | 0 | 1 | 4 | 11 | 8 | 3 |
| Complex karyotype | 1 | 1 | 3 | 8 | 8 | 11 |
| del(17p) | 0 | 0 | 1 | 1 | 3 | 2 |
| del(11q) | 3 | 1 | 4 | 9 | 5 | 7 |
| trisomy 12 | 0 | 0 | 1 | 4 | 3 | 3 |
| del(13q) | 2 | 0 | 2 | 0 | 5 | 16 |
Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b Cohort 100mg Venetoclax (GDC-0199) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1b Cohort 200mg Venetoclax (GDC-0199) | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1b Cohort 400mg Venetoclax (GDC-0199) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 2 Relapsed/Refractory | 1/25 (4%) | 12/25 (48%) | 25/25 (100%) |
| TN1: Phase 2 Treatment Naïve | 1/25 (4%) | 7/25 (28%) | 25/25 (100%) |
| TN2: Phase 2 Treatment Naïve | 1/25 (4%) | 11/25 (44%) | 25/25 (100%) |
| Event | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/3 | 0/3 | 0/6 | 0/25 | 0/25 | 0/25 |
| Atrioventricular block completeCardiac disorders | 0/3 | 1/3 | 0/6 | 0/25 | 0/25 | 0/25 |
| Flu like symptomsGeneral disorders | 0/3 | 1/3 | 0/6 | 0/25 | 0/25 | 0/25 |
| HypertensionVascular disorders | 0/3 | 1/3 | 0/6 | 1/25 | 0/25 | 0/25 |
| Infections and infestations - OtherInfections and infestations | 0/3 | 1/3 | 1/6 | 0/25 | 0/25 | 3/25 |
| Lung infectionInfections and infestations | 0/3 | 1/3 | 1/6 | 1/25 | 1/25 | 2/25 |
| Neutrophil count decreasedInvestigations | 0/3 | 0/3 | 0/6 | 0/25 | 0/25 | 4/25 |
| Chest pain - cardiacCardiac disorders | 0/3 | 0/3 | 0/6 | 2/25 | 0/25 | 0/25 |
| Upper respiratory infectionInfections and infestations | 0/3 | 0/3 | 0/6 | 2/25 | 0/25 | 0/25 |
| Atrial fibrillationCardiac disorders | 0/3 | 0/3 | 0/6 | 0/25 | 2/25 | 1/25 |
| Event | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve |
|---|---|---|---|---|---|---|
| Alanine Aminotransferase increasedInvestigations | 2/3 | 3/3 | 4/6 | 10/25 | 8/25 | 13/25 |
| Allergic RhinitisRespiratory, thoracic and mediastinal disorders | 1/3 | 3/3 | 3/6 | 13/25 | 15/25 | 3/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/3 | 1/3 | 5/6 | 13/25 | 17/25 | 9/25 |
| Aspartate Aminotransferase IncreasedInvestigations | 2/3 | 3/3 | 3/6 | 13/25 | 12/25 | 17/25 |
| BruisingInjury, poisoning and procedural complications | 3/3 | 3/3 | 6/6 | 20/25 | 19/25 | 19/25 |
| DiarrheaGastrointestinal disorders | 2/3 | 2/3 | 6/6 | 19/25 | 17/25 | 24/25 |
| FatigueGeneral disorders | 3/3 | 2/3 | 6/6 | 21/25 | 23/25 | 17/25 |
| HyperglycemiaMetabolism and nutrition disorders | 3/3 | 0/3 | 5/6 | 16/25 | 18/25 | 14/25 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 3/3 | 3/3 | 2/6 | 10/25 | 12/25 | 7/25 |
| HypertensionVascular disorders | 3/3 | 3/3 | 6/6 | 25/25 | 25/25 | 22/25 |
| Age, Categorical(Participants) | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 6 | 19 | 18 | 20 | 67 |
| >=65 years | 1 | 1 | 0 | 6 | 7 | 5 | 20 |
| Sex: Female, Male(Participants) | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 9 | 10 | 8 | 28 |
| Male | 3 | 3 | 5 | 16 | 15 | 17 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 3 | 3 | 6 | 25 | 24 | 23 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| White | 3 | 3 | 6 | 23 | 25 | 22 | 82 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Region of Enrollment(participants) | Phase 1b Cohort 100mg Venetoclax (GDC-0199) | Phase 1b Cohort 200mg Venetoclax (GDC-0199) | Phase 1b Cohort 400mg Venetoclax (GDC-0199) | Phase 2 Relapsed/Refractory | TN1: Phase 2 Treatment Naïve | TN2: Phase 2 Treatment Naïve | Total |
|---|---|---|---|---|---|---|---|
| United States | 3 | 3 | 6 | 25 | 25 | 25 | 87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2015 to primary completion in Dec 2021, 76 months.
Results were first posted in Jan 2026, 4 years 1 month after primary completion.
Of 40 non-industry phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 103. This study's 76 months is close to that.
Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →
Kerry Rogers